Description

2-Pyrimidinamine, 4-(4-Fluoro-1-Naphthalenyl)-6-(1-Methylethyl)-, Monohydrochloride is a high-purity, non-nucleoside reverse transcriptase inhibitor (NNRTI) intermediate of significant pharmaceutical importance. This compound is valued for its role as a critical building block in the synthesis of next-generation antiviral and antiretroviral active pharmaceutical ingredients (APIs). It is primarily sought by research institutions and pharmaceutical manufacturers engaged in the development and scale-up of treatments for viral infections, where supply chain reliability and strict quality control are paramount.

Application

• Pharmaceutical Intermediate: Key synthetic precursor for the production of Diarylpyrimidine (DAPY) class non-nucleoside reverse transcriptase inhibitors (NNRTIs).
• Antiviral Drug Development: Core building block in research and commercial synthesis of drugs targeting HIV-1 and other retroviruses.
• Active Pharmaceutical Ingredient (API) Synthesis: Used in the final or penultimate steps of API manufacturing under current Good Manufacturing Practice (cGMP) conditions.
• Biochemical Research: Serves as a reference standard and a tool compound in virology and medicinal chemistry research for studying drug resistance and mechanism of action.
• Process Chemistry & Scale-Up: Employed in process optimization and kilogram-scale production for clinical trial material and commercial drug supply.

Basic Information

Product Name	2-Pyrimidinamine, 4-(4-Fluoro-1-Naphthalenyl)-6-(1-Methylethyl)-, Monohydrochloride
CAS No.	199864-86-3
Molecular Formula	C₁₇H₁₇FN₄·HCl
Molecular Weight	332.80 g/mol (Free base: 296.34 g/mol)
Synonyms	4-(4-Fluoronaphthalen-1-yl)-6-isopropylpyrimidin-2-amine hydrochloride; Rilpivirine Intermediate; TMC278 Intermediate; 6-Isopropyl-4-(4-fluoro-1-naphthyl)pyrimidin-2-amine hydrochloride; GSK-1901139A; 2-Amino-4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)pyrimidine monohydrochloride; DAPY Intermediate; NNRTI Intermediate CAS 199864-86-3
EINECS	Contact for details

Quality Control

Our production of this pharmaceutical intermediate adheres to stringent quality systems. Every batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We ensure compliance with relevant ICH guidelines for impurities and can support development under cGMP standards for advanced clinical and commercial applications. Certificates of Analysis are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and should be handled in a dry environment to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥98.0%
Water Content (KF)	≤0.5%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Related Substances (HPLC)	Total impurities ≤2.0%; Any single impurity ≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.